Medrate® Solubile 500mg

Description

Medrate® Solubile ad us. vet. is indicated as adjunctive therapy in dogs with life-threatening conditions such as hemorrhagic / traumatic shock.
 
Active ingredients and other ingredients:
Medrate® Solubile ad us. vet. 125 mg:
1 injection vial of 185.1 mg
Powder contains: 
 
Active ingredient:
Methylprednisolone − 21-hydrogen succinate, sodium salt 165.74 mg (equivalent to 125 mg methylprednisolone) 
 
1 ampoule with solvent contains:
Water for injections 2 ml 
 
1 ml of the prepared, ready-to-use solution contains:
Methylprednisolone − 21-hydrogen succinate, sodium salt 82.87 mg (equivalent to 62.5 mg methylprednisolone) 
 
Other ingredients:
Powder:
Sodium dihydrogen phosphate monohydrate
Disodium hydrogen phosphate 
 
Medrate® Solubile ad us. vet. 500 mg:
1 injection bottle of 740 mg
Powder contains: 
 
Active ingredient:
Methylprednisolone − 21-hydrogen succinate, sodium salt 662.95 mg (equivalent to 500 mg methylprednisolone) 
 
1 ampoule with solvent contains:
Water for injections 7.8 ml 
 
1 ml of the prepared, ready-to-use solution contains:
Methylprednisolone − 21-hydrogen succinate, sodium salt 82.87 mg (equivalent to 62.5 mg methylprednisolone) 
 
Other ingredients:
Powder:
Sodium dihydrogen phosphate monohydrate
Disodium hydrogen phosphate
 
Dosage, type and application:
For intravenous or intramuscular use. 
 
The solution to be administered is reconstituted from the powder and solvent. 
 
Depending on the severity of the condition:
15-30 mg methylprednisolone / kg body weight (body weight) correspond to 0.24-0.48 ml Medrate® Solubile ad us. vet. per kg body weight. 
 
The dose is injected slowly over a period of several minutes. 
 
A repeat injection can be given.
 
Special warnings:
No. 
 
Special precautions for use in animals:
Treatment with glucocorticoids such as methylprednisolone can lead to severe infections. If infections occur, the veterinarian should be consulted.
Only the solvent supplied may be used to prepare the solution for injection. 
 
Special precautions for the user: 
 
Avoid skin and eye contact. Wash hands after use. Accidental splashes on the skin should be washed off immediately with soap and water. In the event of accidental contact with the eyes, rinse thoroughly with water. In the event of accidental self-injection, seek medical advice immediately and show the package insert or the label. 
 
Use during pregnancy and lactation:
Due to the inadequately clarified possible teratogenic effects of methylprednisolone, it should only be used during pregnancy if there is a strict indication. Use in nursing animals only after strict indications, as glucocorticoids pass into the milk and growth disorders of the young can occur. 
 
Interactions with other drugs and other forms of interaction:
Increased potassium losses with simultaneous administration of thiazide and loop diuretics. Decreased cardiac glycoside tolerance due to potassium deficiency. Increased risk of gastrointestinal bleeding and ulceration with concomitant use of non-teroidal anti-inflammatory drugs.
Increased need for insulin. Reduced effect with simultaneous administration of enzyme-inducing drugs (e.g. phenytoin, phenobarbital, rifampicin).
Increase in intraocular pressure with simultaneous administration of anticholinergics. 
 
Overdose:
In chronic toxicity studies, one death occurred in dogs given intramuscularly 3 mg / kg body weight prednisolone daily for 108 days. 
The clinical picture of an acute overdose is unknown. A specific antidote is not known. 
 
Incompatibilities:
Not known.
 
Contraindications:
(in the case of long-term systemic use that goes beyond emergency therapy) 
 
Defense weakness, viral infections, septic processes, systemic mycoses, caution with acute infections, active immunization, gastrointestinal ulcers, diabetes mellitus, osteoporosis, hypocalcemia, glaucoma, Cushing’s syndrome, chronic kidney failure, uremia, congestive heart failure
 
Side effects:
The typical side effects of glucocorticoids can occur, particularly with prolonged treatment.
These include: disorders of the electrolyte balance, edema, weight gain, muscle atrophy, inactivity atrophy of the adrenal cortex, immunosuppression, increased risk of infection, gastrointestinal ulcers, growth retardation in young animals, delayed wound healing, skin atrophy, muscle wasting, polyphagia, polydipsia, polyuria, depression , Tendency to thrombosis, hypertension, glaucoma and Cushing’s syndrome, diabetic metabolism.
 
Waiting period:
Not applicable
 
Special storage advice:
Do not store above 25 ° C.
Shelf life of the prepared injection solution: 6 hours
Product group: Medrate Solubile ad us.vet.
Animal species:dogs
Symptoms:Allergies shock treatment
Characteristics:   Glucocorticoid
Active ingredient:Methylprednisolone

Product hierarchy: Pharmaceutical product


Powder and solvent for solution for injection.

 
Target species:
dog